{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:03:21Z","timestamp":1792800201447,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the National Science & Technology Pillar Program of the twelfth Five-Year Plan in China","award":["2012BAI06B02"],"award-info":[{"award-number":["2012BAI06B02"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81670605"],"award-info":[{"award-number":["No. 81670605"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the clinical key projects of Peking University Third Hospital","award":["Y76493-03"],"award-info":[{"award-number":["Y76493-03"]}],"id":[{"id":"https:\/\/ror.org\/04wwqze12","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the key laboratory for Helicobacter pylori infection and upper gastrointestinal diseases in Beijing","award":["No. BZ0371"],"award-info":[{"award-number":["No. BZ0371"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12876-019-1056-3","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T09:02:33Z","timestamp":1564045353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin"],"prefix":"10.1186","volume":"19","author":[{"given":"Zhiqiang","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"issue":"1","key":"1056_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V\/Florence consensus report. Gut. 2017;66(1):6\u201330.","journal-title":"Gut"},{"issue":"12","key":"1056_CR2","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.dld.2014.08.038","volume":"46","author":"Z Song","year":"2014","unstructured":"Song Z, Zhang J, He L, Chen M, Hou X, Li Z, et al. Prospective multi-region study on primary antibiotic resistance of helicobacter pylori strains isolated from Chinese patients. Dig Liver Dis. 2014;46(12):1077\u201381.","journal-title":"Dig Liver Dis"},{"issue":"8","key":"1056_CR3","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/gut.2009.192757","volume":"59","author":"DY Graham","year":"2010","unstructured":"Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143\u201353.","journal-title":"Gut"},{"issue":"1","key":"1056_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","volume":"62","author":"F Megraud","year":"2013","unstructured":"Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34\u201342.","journal-title":"Gut"},{"issue":"2","key":"1056_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/hel.12287","volume":"21","author":"DY Graham","year":"2016","unstructured":"Graham DY. Hp-normogram (normo-graham) for assessing the outcome of H. pylori therapy: effect of resistance, duration, and CYP2C19 genotype. Helicobacter. 2016;21(2):85\u201390.","journal-title":"Helicobacter"},{"issue":"11","key":"1056_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s11882-014-0476-y","volume":"14","author":"E Macy","year":"2014","unstructured":"Macy E. Penicillin and beta-lactam allergy: epidemiology and diagnosis. Curr Allergy Asthma Rep. 2014;14(11):476.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"1056_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/cea.12468","volume":"45","author":"R Mirakian","year":"2015","unstructured":"Mirakian R, Leech SC, Krishna MT, Richter AG, Huber PA, Farooque S, et al. Management of allergy to penicillins and other beta-lactams. Clin Exp Allergy. 2015;45(2):300\u201327.","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"1056_CR8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.anai.2014.02.005","volume":"112","author":"ME Pichichero","year":"2014","unstructured":"Pichichero ME, Zagursky R. Penicillin and cephalosporin allergy. Ann Allergy Asthma Immunol. 2014;112(5):404\u201312.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"1056_CR9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s10620-014-3365-2","volume":"60","author":"JP Gisbert","year":"2015","unstructured":"Gisbert JP, Barrio J, Modolell I, Molina-Infante J, Aisa AP, Castro-Fernandez M, et al. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. Dig Dis Sci. 2015;60(2):458\u201364.","journal-title":"Dig Dis Sci"},{"issue":"10","key":"1056_CR10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/j.1365-2036.2005.02687.x","volume":"22","author":"JP Gisbert","year":"2005","unstructured":"Gisbert JP, Gisbert JL, Marcos S, Olivares D, Pajares JM. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther. 2005;22(10):1041\u20136.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1056_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.dld.2009.06.007","volume":"42","author":"JP Gisbert","year":"2010","unstructured":"Gisbert JP, Perez-Aisa A, Castro-Fernandez M, Barrio J, Rodrigo L, Cosme A, et al. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis. 2010;42(4):287\u201390.","journal-title":"Dig Liver Dis"},{"issue":"3","key":"1056_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12374","volume":"22","author":"S Ono","year":"2017","unstructured":"Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter. 2017;22(3):e12374.","journal-title":"Helicobacter"},{"issue":"3","key":"1056_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.gtc.2015.05.003","volume":"44","author":"DY Graham","year":"2015","unstructured":"Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin N Am. 2015;44(3):537\u201363.","journal-title":"Gastroenterol Clin N Am"},{"issue":"10","key":"1056_CR14","first-page":"1134","volume":"25","author":"H Lu","year":"2013","unstructured":"Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013;25(10):1134\u201340.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"11","key":"1056_CR15","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1136\/gutjnl-2015-309900","volume":"64","author":"W Zhang","year":"2015","unstructured":"Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line helicobacter pylori therapy. Gut. 2015;64(11):1715\u201320.","journal-title":"Gut"},{"issue":"5","key":"1056_CR16","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jemermed.2011.05.035","volume":"42","author":"JD Campagna","year":"2012","unstructured":"Campagna JD, Bond MC, Schabelman E, Hayes BD. The use of cephalosporins in penicillin-allergic patients: a literature review. J Emerg Med. 2012;42(5):612\u201320.","journal-title":"J Emerg Med"},{"issue":"3","key":"1056_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.gtc.2010.08.007","volume":"39","author":"T Furuta","year":"2010","unstructured":"Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for helicobacter pylori infection. Gastroenterol Clin N Am. 2010;39(3):465\u201380.","journal-title":"Gastroenterol Clin N Am"},{"issue":"3","key":"1056_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.otohns.2006.10.007","volume":"136","author":"ME Pichichero","year":"2007","unstructured":"Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg. 2007;136(3):340\u20137.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"8","key":"1056_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/1751-2980.12271","volume":"16","author":"P Bai","year":"2015","unstructured":"Bai P, Zhou LY, Xiao XM, Luo Y, Ding Y. Susceptibility of helicobacter pylori to antibiotics in Chinese patients. J Dig Dis. 2015;16(8):464\u201370.","journal-title":"J Dig Dis"},{"issue":"6","key":"1056_CR20","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1007\/s10620-017-4564-4","volume":"62","author":"W Fu","year":"2017","unstructured":"Fu W, Song Z, Zhou L, Xue Y, Ding Y, Suo B, et al. Randomized clinical trial: esomeprazole, bismuth, levofloxacin, and amoxicillin or cefuroxime as first-line eradication regimens for helicobacter pylori infection. Dig Dis Sci. 2017;62(6):1580\u20139.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"1056_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/jac\/dkf041","volume":"49","author":"Z Samra","year":"2002","unstructured":"Samra Z, Shmuely H, Niv Y, Dinari G, Passaro DJ, Geler A, et al. Resistance of helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime. J Antimicrob Chemother. 2002;49(6):1023\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1056_CR22","first-page":"309","volume":"55","author":"S Fagoonee","year":"2013","unstructured":"Fagoonee S, Astegiano M, Smedile A, Pellicano R. Efficacy of cefixime-based triple therapy for helicobacter pylori eradication: a retrospective study. Panminerva Med. 2013;55(3):309\u201310.","journal-title":"Panminerva Med"},{"issue":"9","key":"1056_CR23","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/gut.31.9.973","volume":"31","author":"M Tatsuta","year":"1990","unstructured":"Tatsuta M, Ishikawa H, Iishi H, Okuda S, Yokota Y. Reduction of gastric ulcer recurrence after suppression of helicobacter pylori by cefixime. Gut. 1990;31(9):973\u20136.","journal-title":"Gut"},{"issue":"3","key":"1056_CR24","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0091-6749(96)70101-X","volume":"98","author":"A Miranda","year":"1996","unstructured":"Miranda A, Blanca M, Vega JM, Moreno F, Carmona MJ, Garcia JJ, et al. Cross-reactivity between a penicillin and a cephalosporin with the same side chain. J Allergy Clin Immunol. 1996;98(3):671\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"3 Suppl","key":"1056_CR25","doi-asserted-by":"publisher","first-page":"13s","DOI":"10.1016\/j.diagmicrobio.2006.12.004","volume":"57","author":"ME Pichichero","year":"2007","unstructured":"Pichichero ME. Use of selected cephalosporins in penicillin-allergic patients: a paradigm shift. Diagn Microbiol Infect Dis. 2007;57(3 Suppl):13s\u20138s.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"1056_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/hel.12052","volume":"18","author":"J Liao","year":"2013","unstructured":"Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013;18(5):373\u20137.","journal-title":"Helicobacter"},{"issue":"9862","key":"1056_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(12)61579-7","volume":"381","author":"JM Liou","year":"2013","unstructured":"Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al. Sequential versus triple therapy for the first-line treatment of helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013;381(9862):205\u201313.","journal-title":"Lancet"},{"issue":"1","key":"1056_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.gastro.2013.03.050","volume":"145","author":"J Molina-Infante","year":"2013","unstructured":"Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013;145(1):121\u2013128.e121.","journal-title":"Gastroenterology"},{"issue":"4","key":"1056_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/hel.12046","volume":"18","author":"P Su","year":"2013","unstructured":"Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, et al. Antibiotic resistance of helicobacter pylori isolated in the southeast coastal region of China. Helicobacter. 2013;18(4):274\u20139.","journal-title":"Helicobacter"},{"issue":"2","key":"1056_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/hel.12242","volume":"21","author":"L Zhou","year":"2016","unstructured":"Zhou L, Zhang J, Song Z, He L, Li Y, Qian J, et al. Tailored versus triple plus bismuth or concomitant therapy as initial helicobacter pylori treatment: a randomized trial. Helicobacter. 2016;21(2):91\u20139.","journal-title":"Helicobacter"},{"issue":"4","key":"1056_CR31","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s10620-005-2549-1","volume":"50","author":"M Rodriguez-Torres","year":"2005","unstructured":"Rodriguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF, Aponte-Rivera E, Marxuach-Cuetara AM, Rodriguez-Orengo JF, et al. High eradication rates of helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig Dis Sci. 2005;50(4):634\u20139.","journal-title":"Dig Dis Sci"},{"issue":"1 Pt 2","key":"1056_CR32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1440-1746.2006.04171.x","volume":"21","author":"M Matsushima","year":"2006","unstructured":"Matsushima M, Suzuki T, Kurumada T, Watanabe S, Watanabe K, Kobayashi K, et al. Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against helicobacter pylori infection. J Gastroenterol Hepatol. 2006;21(1 Pt 2):232\u20136.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"1056_CR33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2169\/internalmedicine.53.1677","volume":"53","author":"T Furuta","year":"2014","unstructured":"Furuta T, Sugimoto M, Yamade M, Uotani T, Sahara S, Ichikawa H, et al. Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin. Intern Med. 2014;53(6):571\u20135.","journal-title":"Intern Med"},{"issue":"5","key":"1056_CR34","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/gutjnl-2015-311019","volume":"65","author":"MP Dore","year":"2016","unstructured":"Dore MP, Lu H, Graham DY. Role of bismuth in improving helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870\u20138.","journal-title":"Gut."},{"issue":"7","key":"1056_CR35","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/apt.13346","volume":"42","author":"EA Marcus","year":"2015","unstructured":"Marcus EA, Sachs G, Scott DR. Colloidal bismuth subcitrate impedes proton entry into helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Aliment Pharmacol Ther. 2015;42(7):922\u201333.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1056_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cgh.2013.05.028","volume":"12","author":"DY Graham","year":"2014","unstructured":"Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12(2):177\u2013186.e173 Discussion e112\u2013173.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1056_CR37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/1751-2980.12334","volume":"17","author":"ZQ Song","year":"2016","unstructured":"Song ZQ, Zhou LY. Esomeprazole minocycline metronidazole and bismuth as first-line and second-line regimens for helicobacter pylori eradication. J Dig Dis. 2016;17(4):260\u20137.","journal-title":"J Dig Dis"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1056-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-019-1056-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1056-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T19:13:14Z","timestamp":1595531594000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-019-1056-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1186\/s12876-019-1056-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,25]]},"assertion":[{"value":"14 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Each patient provided signed informed consent. This trial had approval from the Ethics Committee of Peking University Third Hospital, Beijing, China, and conformed to the Declaration of Helsinki following Good Clinical Practice. All authors evaluated study results and approved the final manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}